Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) & Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®:) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen
Celgene has developed a new program called Fast Track for First Prescription™ to help eligible patients receive their first prescriptions for a Celgene product quickly and efficiently.
Celgene's Patient Support Coordinators assist patients and healthcare providers to navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Revlimid.
Revlimid® is an immunomodulatory agent. It is a drug that can modify or regulate the functioning of the immune system. These agents appear to have multiple actions, including both anticancer and anti-inflammatory activities.
A quarterly publication featuring the most up-to-date information on research advances and new therapies for the treatment for multiple myeloma. CITINGS provides physicians and other health care professionals with references and Internet links to the most current U.S. and international journal articles, abstracts, and white papers. Several issues have been published on Revlimid™.
Research presented at the British Society for Haematology Annual Meeting demonstrates that REVLIMID® has the ability to add years to myeloma patients’ lives, and that these years fall within the quality-adjusted life years, or QALY guidelines. QALY is a measurement of cost-effectiveness of a drug based on quality of life achieved, not just the number of years.
Such a listing not only sets the groundwork for Medicare reimbursement of frontline Revlimid, but may ease the process of reimbursement from other insurers as well.
Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID® and other Drugs in Newly Diagnosed Myeloma
Patients, Advocates and Experts Applaud Positive Opinion from EU Advisory Committee
IMF Addresses the High Cost of Cancer Therapies
We are pleased that REVLIMID has been approved, but we are concerned about the high cost of cancer therapies in the current reimbursement environment. On the International Myeloma Foundation hotline we hear daily from myeloma patients who are forced to choose medical alternatives when costs are too high and reimbursement too low. We will look into reimbursement for Revlimid and coverage under the various Medicare plans and help our patients through the system. As patient advocates we will work with Celgene, with other pharmaceutical companies, and the government to help ensure that therapies are available to all who need them and are not out of reach because of price or reimbursement.
The International Myeloma Foundation – supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said FDA approval of REVLIMID® (lenalidomide) for patients with myeloma is a major new addition to the group of treatments that together have the potential to significantly extend patients' lives.
Breakthroughs in the treatment of blood cancer were presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta. In one of the findings, Revlimid® was shown to extend life for patients taking the drug. This is a major advancement as the majority of multiple myeloma can now consider multiple myeloma a chronic, manageable condition. Video featuring patients Hardy Jones and Paul Nicholss and the IMF's Dr. Brian Durie.
The International Myeloma Foundation is pleased to report another important step toward approval of Revlimid for multiple myeloma, this time in Europe.
The FDA has granted a "priority review" for Revlimid in combination with dexamethasone for myeloma patients who have been treated with at least one previous regimen.
Revlimid® (Lenalidomide) is an important new agent for the treatment of myeloma. It has shown great promise as both a single agent and in combination with dexamethasone and other drugs. With use of Revlimid there is much less risk of nerve toxicity than with thalidomide, which is one of the reasons patients have been eagerly awaiting access to it.
Revlimid from the Celgene Corporation was just approved by the Food and Drug Administration to treat certain patients with a malignant blood condition called myelodysplastic syndrom (MDS.) The IMF looks forward to rapid review of Revlimid for Multiple Myeloma.
Revlimid from the Celgene Corporation was just approved by the Food and Drug Administration to treat certain patients with a malignant blood condition called MDS.
The IMF today is pleased to inform physicians, patients and their families that the clinical trial of Revlimid® plus dexamethasone in people newly diagnosed with multiple myeloma has resumed.
Celgene Corporation reported that Revlimid, also known as lenalidomide, has shown outstanding results in the treatment of relapsed or refractory myeloma in two Phase III clinical trials
The Unknown Patient reports from the annual meeting of the American Society of Clinical Oncology (ASCO) on the current status and potential availability of the promising new drug, Revlimid.
An Independent Data Monitoring Board has advised Celgene to unblind two Phase III clinical trials of Revlimid (lenalidomide) in patients with relapsed or refractory myeloma involving over 700 patients. The results are positive and exceed original expectations.
Celgene Corporation reported that Revlimid, also known as lenalidomide, has shown outstanding results in the treatment of relapsed or refractory myeloma in two Phase III clinical trials.
step 1: get the correct diagnosis
publications
back
print
related articles
Be the first to comment